Genflow Biosciences PLC Announces Institutional Investment
Genflow Biosciences (LSE:GENF/OTCQB:GENFF) has secured an institutional investment of £434,083 through a binding offer for 41,341,324 Ordinary Shares at 1.05p per share. The shares will be issued after April 9, 2025, with trading admission expected around April 10, 2025.
Company Director Eric Leire intends to invest an additional £50,000 under the same terms. Following the share issuance, the company's enlarged issued share capital will comprise 391,047,942 ordinary shares.
The funding, combined with previous government grants, will support Genflow's 2025 programs, particularly a newly launched proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs. The trial will involve 28 dogs aged 10+ years, conducted with CRO Syngene, focusing on biological age estimation, muscle strength, muscle mass, mitochondrial function, coat quality, and overall health indicators over a 12-month period.
Genflow Biosciences (LSE:GENF/OTCQB:GENFF) ha ottenuto un investimento istituzionale di £434,083 attraverso un'offerta vincolante per 41,341,324 azioni ordinarie a 1,05p per azione. Le azioni saranno emesse dopo il 9 aprile 2025, con l'ammissione al trading prevista intorno al 10 aprile 2025.
Il Direttore dell'azienda Eric Leire intende investire ulteriori £50,000 alle stesse condizioni. Dopo l'emissione delle azioni, il capitale sociale emesso dell'azienda sarà composto da 391,047,942 azioni ordinarie.
Il finanziamento, insieme ai precedenti sovvenzioni governative, supporterà i programmi del 2025 di Genflow, in particolare un trial clinico di prova di concetto appena lanciato che valuta la loro terapia genica SIRT6-centenarian nei cani anziani. Il trial coinvolgerà 28 cani di età superiore ai 10 anni, condotto con CRO Syngene, concentrandosi sulla stima dell'età biologica, forza muscolare, massa muscolare, funzione mitocondriale, qualità del pelo e indicatori di salute generale nel corso di un periodo di 12 mesi.
Genflow Biosciences (LSE:GENF/OTCQB:GENFF) ha asegurado una inversión institucional de £434,083 a través de una oferta vinculante por 41,341,324 acciones ordinarias a 1.05p por acción. Las acciones se emitirán después del 9 de abril de 2025, con la admisión al comercio esperada alrededor del 10 de abril de 2025.
El Director de la empresa, Eric Leire, tiene la intención de invertir £50,000 adicionales bajo los mismos términos. Tras la emisión de acciones, el capital social emitido de la empresa estará compuesto por 391,047,942 acciones ordinarias.
La financiación, combinada con las subvenciones gubernamentales anteriores, apoyará los programas de Genflow para 2025, especialmente un ensayo clínico de prueba de concepto recién lanzado que evalúa su terapia génica SIRT6-centenarian en perros ancianos. El ensayo involucrará a 28 perros de más de 10 años, realizado con CRO Syngene, centrándose en la estimación de la edad biológica, la fuerza muscular, la masa muscular, la función mitocondrial, la calidad del pelaje y los indicadores de salud general durante un período de 12 meses.
Genflow Biosciences (LSE:GENF/OTCQB:GENFF)는 £434,083의 기관 투자를 확보하였으며, 1.05p의 주가로 41,341,324주를 위한 구속력 있는 제안을 통해 이루어졌습니다. 주식은 2025년 4월 9일 이후에 발행될 예정이며, 거래 승인은 2025년 4월 10일경에 예상됩니다.
회사의 이사인 Eric Leire는 동일한 조건으로 추가로 £50,000를 투자할 계획입니다. 주식 발행 후, 회사의 확대된 발행 주식 자본은 391,047,942주로 구성될 것입니다.
이번 자금 조달은 이전 정부 보조금과 결합되어 Genflow의 2025 프로그램을 지원할 예정이며, 특히 노령견을 대상으로 한 SIRT6-센테나리안 유전자 치료의 개념 증명 임상 시험이 새롭게 시작됩니다. 이 시험은 10세 이상의 28마리의 개를 대상으로 하며, CRO Syngene과 함께 진행되며, 생물학적 나이 추정, 근력, 근육량, 미토콘드리아 기능, 털의 질, 전반적인 건강 지표 등을 12개월 동안 평가합니다.
Genflow Biosciences (LSE:GENF/OTCQB:GENFF) a sécurisé un investissement institutionnel de £434,083 grâce à une offre contraignante pour 41,341,324 actions ordinaires à 1,05p par action. Les actions seront émises après le 9 avril 2025, avec une admission à la négociation prévue autour du 10 avril 2025.
Le directeur de l'entreprise, Eric Leire, prévoit d'investir un montant supplémentaire de £50,000 selon les mêmes conditions. Suite à l'émission des actions, le capital social émis de l'entreprise sera composé de 391,047,942 actions ordinaires.
Le financement, combiné avec les subventions gouvernementales précédentes, soutiendra les programmes de Genflow pour 2025, en particulier un essai clinique de preuve de concept récemment lancé qui évalue leur thérapie génique SIRT6-centenaire chez les chiens âgés. L'essai impliquera 28 chiens de plus de 10 ans, mené avec CRO Syngene, en se concentrant sur l'estimation de l'âge biologique, la force musculaire, la masse musculaire, la fonction mitochondriale, la qualité du pelage et les indicateurs de santé générale sur une période de 12 mois.
Genflow Biosciences (LSE:GENF/OTCQB:GENFF) hat eine institutionelle Investition in Höhe von £434,083 durch ein verbindliches Angebot für 41,341,324 Stammaktien zu 1,05p pro Aktie gesichert. Die Aktien werden nach dem 9. April 2025 ausgegeben, wobei die Handelszulassung um den 10. April 2025 erwartet wird.
Der Unternehmensdirektor Eric Leire beabsichtigt, zusätzlich £50,000 zu denselben Bedingungen zu investieren. Nach der Aktienausgabe wird das erweiterte ausgegebene Aktienkapital des Unternehmens aus 391,047,942 Stammaktien bestehen.
Die Finanzierung, kombiniert mit vorherigen staatlichen Zuschüssen, wird die Programme von Genflow für 2025 unterstützen, insbesondere eine neu gestartete Proof-of-Concept-Studie, die ihre SIRT6-Centenarian-Gentherapie bei älteren Hunden bewertet. Die Studie wird 28 Hunde über 10 Jahren umfassen und wird mit CRO Syngene durchgeführt, wobei der Schwerpunkt auf der Schätzung des biologischen Alters, der Muskelkraft, der Muskelmasse, der mitochondrialen Funktion, der Fellqualität und allgemeinen Gesundheitsindikatoren über einen Zeitraum von 12 Monaten liegt.
- Secured £434,083 in institutional investment
- Additional £50,000 investment commitment from Director Eric Leire
- Launch of proof-of-concept gene therapy trial in aged dogs
- Previous government grants support funding
- Partnership with renowned CRO Syngene for trial execution
- Share issuance will cause dilution for existing shareholders
- New shares cannot be issued until April 9, 2025 due to Prospectus Rules limitations
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Genflow Secures £434,083 from a Leading Institution and Launches a Gene Therapy Trial in Aged Dogs
LONDON, UNITED KINGDOM / ACCESS Newswire / March 26, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") the only longevity company listed in Europe, is pleased to announce it has received a binding offer from a major institution for an equity investment totalling £434,083 (before expenses).
The investor has applied for 41,341,324 Ordinary Shares of £0.0003 each at a price of 1.05p (the "New Ordinary Shares"). The number of New Ordinary Shares applied for by the subscriber is the maximum number of shares (on a fully diluted basis) available to the Company to issue without the need to produce a Prospectus. These New Ordinary Shares cannot be issued until after 9 April 2025 when the Company's headroom, under the Prospectus Rules, increases.
An application will be made to the Main Market of the London Stock Exchange, and admission of the New Ordinary Shares to trading is expected on or around 10 April 2025 ("Admission"). The New Ordinary Shares will, when issued, rank pari passu with the Company's existing Ordinary Shares.
Director's Intended Participation
Eric Leire, a Director of the Company, intends to invest £50,000 on the same terms as the investment outlined above on the basis that such participation falls under the employee offer exemption under Article 1(4)(i) and 1(5)(h) of the UK Prospectus Regulation, and further, subject to the Company not being in a Closed Period at the time of such investment and the same being subject to the Company's share dealing policy.
A further announcement will be made in relation to this in due course.
Total Voting Rights
For the purpose of the Disclosure Guidance and Transparency Rules, following Admission the enlarged issued share capital of the Company will comprise 391,047,942 ordinary shares. For the avoidance of doubt, this excludes any intended equity participation by Eric Leire.
The Company does not hold any shares in treasury. The above figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure Guidance and Transparency Rules.
Tamara Joseph, Chair of the Company, commented "We are extremely pleased to have been approached by an institution who wishes to support Genflow in its journey in pioneering gene therapies to decelerate the aging process. The use of these proceeds will accelerate the Company's proposed studies and trials in aged dogs, an issue which has attracted a great deal of press coverage,including in recent weeks."
Use of Proceeds
This investment, combined with previously awarded government grants, will accelerate the Company's planned 2025 programs including launching a clinical trial in aged dogs.
Genflow has commenced a proof-of-concept clinical trial to evaluate the safety and efficacy of its proprietary SIRT6-centenarian gene therapy targeting age-related decline in dogs.
The Company will treat the dogs for 6 months and assess the safety and efficacy of our therapy for the following 6 months. This is a randomized, controlled trial with 28 dogs aged 10+ years, conducted with the renowned CRO, Syngene. Genflow will compare recipient dogs of intravenous injections of proprietary SIRT6 gene therapy versus untreated control group. Endpoints will include biological age estimation (via GRIM methylation clock), muscle strength, muscle mass, mitochondrial function, coat quality and overall health indicators.
"As a devoted dog owner myself, I have a 9-year-old golden retriever, I know firsthand the desire we all share for more happy, healthy years of with our beloved pets," said Dr. Eric Leire, CEO of Genflow. "Our goal is not just to extend their lifespan, but to enhance their quality of life. By targeting biological aging in dogs, we also can unlock groundbreaking insights that could revolutionize both veterinary and human medicine. This research has the potential to reshape the way we approach aging, offering hope for longer, healthier lives for all."
Further updates on the progress of the study will be provided in due course.
Contacts
Genflow Biosciences | Harbor Access |
Dr Eric Leire, CEO | Jonathan Paterson, Investor Relations |
+32-477-495-881 | +1 475 477 9401 |
|
Corporate Broker |
|
Capital Plus Partners Ltd | |
Jon Critchley, +44 0203 821 6168 |
|
|
|
About Genflow Biosciences
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Expected to begin in 2025, Genflow's clinical trial aims to explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and Twitter/X.
DISCLAIMER
The contents of this announcement have been prepared by, and are the sole responsibility of, the Company.
This announcement may contain forward-looking statements. The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words "anticipate", "believe", "continue", "could", "estimate", "expect", "intend", "may", "might", "plan", "possible", "potential", "predict", "project", "seek", "should", "would" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
Forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions.
Any forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and Transparency Rules of the FCA or the UK Market Abuse Regulation.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Genflow Biosciences PLC
View the original press release on ACCESS Newswire
FAQ
What is the size and price of Genflow's (GENFF) latest institutional investment?
When will GENFF's new shares begin trading on the London Stock Exchange?
How many dogs will participate in Genflow's (GENFF) gene therapy trial?
What are the key endpoints of Genflow's (GENFF) dog clinical trial?
How long will Genflow's (GENFF) dog gene therapy trial last?
